RFK Indefinitely Postponed A Critical Meeting — And It Could Have 'Devastating Effects' On All Of Us
One of the latest changes is RFK Jr's postponement of a preventive health panel meeting by the United States Preventive Services Task Force (USPSTF), which was scheduled for July 10 and the rumored dismissal of all task force members, as reported by the Wall Street Journal.
The USPSTF sets guidelines for preventive health screenings for conditions such as diabetes, depression and cancer in children and adults. Insurance companies are then required to cover these screenings based on the USPSTF's guidelines.
This news comes not long after Kennedy postponed the meeting of the Advisory Committee on Immunization Practices (ACIP), which sets vaccine recommendations, and replaced the entire committee with individuals known to spread vaccine and health misinformation, according to earlier HuffPost reporting.
The changes to the USPSTF meeting and task force members is worrisome for a few reasons and could directly impact your health. Here's what doctors want you to know:
This task force sets preventive screening recommendations. Changes or delays to the meeting schedule can mean missed diagnoses or changes to what insurance companies cover.
The United States Preventive Services Task Force, which was formed in 1984, is a group of non-partisan volunteers who are 'nationally recognized experts' in the fields of primary care, prevention and evidence-based medicine, according to the USPTF website.
All members are screened for biases, are chosen through public nomination and appointed by the Health and Human Services secretary. They serve four-year terms with new task force members rotating in each year.
'The cancellation of this specific task force ... is going to affect every American if [Kennedy and the U.S. Department of Health and Human Services does] what they did to the ACIP and fire or remove the 16 independent medical experts who really scour the literature and then grade the evidence for each of their recommendations,' Dr. Anita Patel, a pediatric critical care doctor in Washington, D.C., told HuffPost. Once again, this hasn't been done yet, but it is allegedly in the works.
One of the significant roles of the task force is to make recommendations and guidelines for preventative care services such as mammograms, colonoscopies, depression screenings and more, said Patel. Insurance companies are then required to cover these screenings and services as part of the Affordable Care Act. Doctors across the country also follow these guidelines when recommending health services for patients.
In response to the reports of the dismissal of current task force members, the American Medical Association sent a letter to RFK Jr. in support of the task force in which they said, 'USPSTF plays a critical, non-partisan role in guiding physicians' efforts to prevent disease and improve the health of patients by helping to ensure access to evidence-based clinical preventive services.'
Sen. Elizabeth Warren (D-Mass.) and Sen. Angus King (I-Maine) also backed the task force by introducing a resolution that underscores the importance of the group, according to NPR.
'If the [task force] is unable to continue its work, this could have devastating effects on access to preventive services,' Dr. Oni Blackstock, a primary care physician and executive director of Health Justice, a racial and health equity consultancy, told HuffPost via email.
'We [already] know millions of Americans are at risk for losing their Medicaid,' Blackstock said, referring to the nearly $1 trillion cuts in Medicaid as part of the so-called Big, Beautiful Bill.
'Now, many others who have insurance coverage will be at risk for losing no-cost coverage of preventive care services,' added Blackstock.
It's worth knowing that the meeting is currently postponed; it's not clear when it will happen instead, and who will be part of the task force when that time comes. But, as of now, what the task force recommends hasn't changed.
'Canceling the USPSTF meeting without a clear plan to reschedule puts essential, evidence-based health guidance at risk, including continued access to preventive services that millions of Americans rely on, from cancer and diabetes screenings to depression checks to support for breastfeeding,' Dr. David Higgins, a pediatrician and preventive medicine specialist at the University of Colorado Anschutz Medical Campus, told HuffPost via email.
Any delays to the task force's meeting schedule can also cause issues.
'Delays or disruptions can mean delayed diagnoses, missed opportunities for early treatment, and ultimately, worse health outcomes,' added Higgins.
Not only do these changes threaten the guidance from the task force, but they 'affect whether a patient catches their cancer early enough or a person with chronic heart disease gets optimal treatment,' he noted.
The task force was recently criticized for being 'woke,' which some experts think is why it's being targeted now.
'Unfortunately, this [postponement] fits a troubling pattern of political interference in scientific and public health processes,' Higgins said.
Just a few days after Kennedy told panel members that the preventive health meeting was postponed, 'The American Conservative' published an essay titled 'Time for Kennedy to Kill the USPSTF.' The article claimed the task force is 'woke' and follows 'left-wing ideological orthodoxy' and is part of the 'deep state,' among other things.
'The claim that the task force is driven by 'woke' ideology is a political talking point, not a reflection of how the USPSTF actually operates,' said Higgins.
'Their work is based on a rigorous review of scientific evidence. Identifying and addressing disparities in health outcomes is part of delivering high-quality care,' Higgins added.
It's well-established that certain demographics do have worse health care outcomes; Black people have higher rates of maternal mortality than other groups, upward of 50% of Latinx folks are predicted to be diagnosed with diabetes, Black people are 30% more likely to have asthma than white people and the list goes on.
The task force should be considering how race and gender impacts health outcomes. Blackstock noted that USPSTF hasn't always done this, but that is changing.
'It's lacked community voices and, for a long time, didn't focus on health equity or racism's impact on health and was not focused on ensuring diverse representation among its members,' Blackstock said.
Recently, though, this has changed, and the task force has worked to address these issues, Blackstock added.
'It has taken steps to formalize the use of inclusive language, and to flag if data is missing for a population, particularly those that are minoritized,' Blackstock said.
The group is also piloting an equity checklist that helps integrate equity throughout the screening recommendation process, Blackstock noted.
These recent steps put a target on USPSTF's back, she said.
'I believe this is why the [task force] is being targeted, because it is paying attention to health inequities and racism's harmful effects on health,' Blackstock said.
Patel added that USPSTF isn't taking care away from white Americans. Instead, it's 'trying to level the playing field so that everyone got equal care,' Patel noted.
'But, of course, [critics of the task force] saw the term 'diversity' or 'equity' and really tried to blow up one part of a much larger organization to play to their base and say, 'Hey, these guys are woke idiots,'' Patel said.
USPSTF is now trying to advance medicine and make sure everyone, no matter where they live or what they look like, has access to preventive health screenings.
The task force is here to 'take out the inherent racism that we've had in medicine for decades that has been really unduly perpetuated,' Patel noted.
While racism does certainly still exist in medicine, awareness allows medical professionals to address any biases and make sure everyone gets the care they deserve regardless of their race, socioeconomic background or ethnicity, Patel noted.
'It's an evil thing to walk back all of these medical and diversity advancements that we've made in the past decade just because they want to pander to their base. It's unconscionable,' Patel said.
Related...
Experts Say Trump's Big Bill Will Shut Down This 1 Type Of Hospital — And It'll Impact Multitudes
COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why
RFK Jr. Keeps Telling A Flat-Out Lie About Childhood Vaccines — And Doctors Are Sick Of It
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Ultimate Pet Nutrition Launches Mobility Renew, A Breakthrough Joint Support Formula for Dogs
A Veterinarian-Formulated Soft Chew Joint Support Supplement Designed to Promote Flexibility, Soothe Stiffness, and Support Long-Term Mobility in Dogs LOS ANGELES, Aug. 5, 2025 /PRNewswire/ -- Ultimate Pet Nutrition® proudly announces the launch of Mobility Renew™, a veterinarian-developed soft chew supplement designed to support canine joint health, flexibility, and comfort. Crafted by renowned veterinarian Dr. Gary Richter, this premium formula combines clinically-studied ingredients to help dogs of all ages maintain active, comfortable lives.* "What looks like 'slowing down' is often discomfort," explains Dr. Richter. "I developed Mobility Renew to help improve their comfort and activity. A lot of research shows UCII collagen is more effective than glucosamine for joint support. Combined with hyaluronic acid, omega-3s, eggshell membrane, boswellia, and ashwagandha, I believe Mobility Renew is the most powerful joint supplement for dogs on the market."* Mobility Renew is a step above the conventional joint support supplements we have been using for the past twenty years. All this time, we have been largely relying on glucosamine and chondroitin for joints. While these compounds have their benefits, the UC-II collagen in Mobility Renew is much more effective, providing joint and cartilage support and comfort than the ingredients in yesterday's supplements. While the UC-II collagen alone can provide effective relief, the addition of joint support, antioxidants, and omega-3 fats helps promote a healthy joint environment in ways that the older supplements can't. The ingredients in Mobility Renew could be the future of supporting and maintaining optimal joint health in our pets.* What is Ultimate Pet Nutrition Mobility Renew?Ultimate Pet Nutrition Mobility Renew is an advanced hip and joint supplement formulated to support healthy joint function, reduce stiffness, and support cartilage and connective tissue in dogs. This daily soft chew is ideal for aging dogs, active breeds, or any pup experiencing occasional joint discomfort due to normal activity.* Featuring a synergistic blend of premium ingredients—including UC-II® Collagen, MSM, Eggshell Membrane, Salmon Oil, Hyaluronic Acid, and Boswellia—Mobility Renew™ offers comprehensive support for joint mobility and comfort. Each soft chew is designed to help ease joint stiffness, support cartilage development, and maintain healthy bone and joint function.* What sets Ultimate Pet Nutrition Mobility Renew apart from other dog joint supplements is its focus on clinically backed ingredients that can help improve mobility and flexibility. It's an ideal choice for pet parents seeking a natural, holistic approach to joint care. Plus, it's easy-to-administer soft chew format makes it simple to add to your dog's daily routine (as in, no need to hide in peanut butter to get them to eat it!).* Key Ingredients in Ultimate Pet Nutrition Mobility Renew UC-II® Collagen: A patented form of undenatured type II collagen that supports joint comfort, flexibility, and healthy joint function by targeting the root causes of stiffness. * Methylsulfonylmethane (MSM): A naturally occurring compound that supports joint health by promoting normal recovery after exercise. * Eggshell Membrane: Rich in naturally occurring compounds like collagen, elastin, and glycosaminoglycans, which are crucial for top-notch joint health.* Salmon Oil: Packed with omega-3 fatty acids, which have been shown to support healthy joint mobility and reduce occasional discomfort in dogs.* Hyaluronic Acid: A naturally occurring compound that acts as a lubricant for the joints, helping to support the joints during activity.* Boswellia: A natural herb that supports smooth, comfortable joint movement, especially after exercise or during periods of increased activity.* Ultimate Pet Nutrition Mobility Renew FAQ How do I use Ultimate Pet Nutrition Mobility Renew? To use Ultimate Pet Nutrition Mobility Renew, give the appropriate number of soft chews to your dog once per day based on the chart. Where can I purchase Ultimate Pet Nutrition Mobility Renew? Ultimate Pet Nutrition Mobility Renew can be purchased on for $49.95. About Ultimate Pet NutritionFounded by Dr. Gary Richter, Ultimate Pet Nutrition believes optimal nutrition is the key to a happy life. It's our mission to support your pet's health with premium quality food, treats, and supplements developed by Dr. Richter himself—because we understand your pet is like family, and they deserve only the best. In 2025, Dr. Richter teamed up with award-winning actor Rob Lowe, a dog dad himself and one of the most renowned actors and health advocates in the world, to spread the word about good nutrition and form a community that helps your pet live a happier, healthier life. Best-selling products include our popular freeze-dried raw dog food, Nutra Complete for Dog, and the popular freeze-dried raw treats, Nutra Bites. Ultimate Pet Nutrition products are also available on Amazon. Follow Ultimate Pet Nutrition on Instagram @ultimatepetnutrition and YouTube @ultimatepetnutrition. For retail opportunities, contact retail@ About Dr. Gary RichterDr. Gary Richter is a leader in integrating advanced Western medicine and Eastern holistic practices to provide comprehensive care for pets. As the founder of Ultimate Pet Nutrition, his unwavering dedication and passion for animals have earned him and his animal hospitals over 30 prestigious awards, including "Best Veterinarian" and "Best Alternative Medicine Provider." Dr. Richter is also the international best-selling author of The Ultimate Pet Health Guide and his latest books, Longevity for Cats and Longevity for Dogs, offering pet owners 'biohacking for pets" insight to help their pets live healthier, happier lives. To learn more, visit or follow him on Instagram @petvetexpert. *All pets are unique. Your results can and will vary. Press Contact:Laura Baumgartner - Asylum PRlbaumgartner@ View original content to download multimedia: SOURCE Ultimate Pet Nutrition Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic's Scientific Advisory Board
SAN DIEGO, August 05, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced that Ray Deshaies, PhD, has joined its scientific advisory board. A biochemist and cell biologist, Dr. Deshaies most recently led global research for Amgen following a distinguished academic career at the California Institute of Technology. "I am deeply impressed with Iambic's team, its platform and application of AI and machine learning to address some of the most complex challenges in cancer and drug discovery," said Dr. Deshaies. "Iambic has differentiated itself by using its technology to uncover truly differentiated oncology candidates and rapidly advancing them into the clinic. I look forward to supporting the team's breakthrough science as they work to bring new therapies to patients." Prior to Amgen, Dr. Deshaies was a professor of biology at Caltech and an investigator at the Howard Hughes Medical Institute. His research focused on mechanisms and regulation of protein homeostasis in eukaryotic cells, with a particular focus on the ubiquitin-proteasome system and the degradation of proteins – work that provided the biochemical foundation for his lab's discovery of proteolysis-targeting chimeras (PROTACS) as a new class of candidate therapeutics. He also co-founded the biotechnology companies Proteolix and Cleave Biosciences and is a member of the American Academy of Arts and Sciences and the National Academy of Sciences. "We are thrilled to have Ray join our SAB and look forward to collaborating with him as we shape our pipeline of clinical programs and broaden the potential of our platform to unlock new targets for a range of critical disease areas," said Tom Miller, PhD, Iambic's co-founder and CEO. "Ray's achievements as a scientist, an innovator and a builder of world-class research organizations, make him an ideal partner as we continue to scale and define opportunities enabled by our AI-driven discovery engine." About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 11-12, 2025 Location: Virtual Canaccord Genuity 45th Annual Growth Conference Fireside Chat: August 13, 2025, at 2:30 PM ET Location: Boston, MA The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data